RecruitingPhase 1NCT06613360

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)

Sponsor

Cullinan Therapeutics Inc.

Enrollment

24 participants

Start Date

Jan 21, 2025

Study Type

INTERVENTIONAL

Conditions

SLE SLE (Systemic Lupus)

Summary

Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CLN-978 for people with sle and sle (systemic lupus). The study is currently recruiting participants at 20 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCLN-978

Specified dose on specified days

Locations(20)

AARA Clinical Research

Avondale, Arizona, United States

AARA Clinical Research

Tucson, Arizona, United States

Omega Research Group

Orlando, Florida, United States

University of Iowa

Iowa City, Iowa, United States

Columbia University Medical Center

New York, New York, United States

University of Rochester Medical Center

Rochester, New York, United States

Regional One Health

Memphis, Tennessee, United States

Stryde Research

Plano, Texas, United States

Tranquil Clinical Research

Webster, Texas, United States

Intermountain Health

Salt Lake City, Utah, United States

Royal Melbourne Hospital

Parkville, Australia

Osteoporosis Solutions

Victoria Park, Australia

Multi profile Hospital for Active Treatment Sveta Sofia

Sofia, Bulgaria

CHU de Nantes

Nantes, France

University Hospital Saint Etienne

Saint-Priest-en-Jarez, France

Centre Hospitalier Universitaire de Toulouse

Toulouse, France

ARENSIA Exploratory Medicine, LLC

Tbilisi, Georgia

Timofei Moșneaga Republican Clinical Hospital

Chisinau, Moldova

ARENSIA Exploratory Medicine S.R.L.

Bucharest, Romania

Arensia Exploratory Medicine

Cluj-Napoca, Romania

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06613360

Related Trials

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

NCT072376597 locations

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

NCT068399761 location

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

NCT0726087727 locations

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

NCT065486071 location